Adaptive Biotechnologies announced the launch of its clonoSEQ Assay to detect minimal residual disease, MRD, in blood for patients with diffuse large B-cell lymphoma, DLBCL. clonoSEQ can assess a patient’s MRD status in DLBCL by measuring ctDNA, the fragments of DNA released into the blood from dying cancer cells which can serve as a measure of tumor burden. clonoSEQ is available in DLBCL as a CLIA-validated laboratory developed test, and beginning this week the company will accept DLBCL blood samples in Streck tubes. "We are excited to continue to expand access to clonoSEQ as a highly specific and less invasive tool for DLBCL monitoring which will complement the current standard imaging methods," said Nitin Sood, chief commercial officer, MRD, Adaptive Biotechnologies. "By measuring ctDNA in blood, clonoSEQ provides clinicians with a sensitive and quantitative assessment of disease burden so that they can detect relapse sooner and are better equipped to create a more precise treatment plan for each patient."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ADPT:
- Adaptive Biotechnologies Announces Launch of clonoSEQ® to Assess Minimal Residual Disease (MRD) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Using Circulating Tumor DNA (ctDNA)
- Adaptive Biotechnologies to Participate in the Piper Sandler Healthcare Conference
- New Survey Reveals the Majority of Myeloma Patients That Undergo Minimal Residual Disease (MRD) Testing Find a Clear Clinical or Emotional Benefit from Results
- Adaptive Biotechnologies participates in a conference call with JPMorgan
- Society for Immunotherapy of Cancer to hold a meeting